USS Investment Management Ltd Grows Holdings in Boston Scientific Corporation $BSX

USS Investment Management Ltd increased its holdings in Boston Scientific Corporation (NYSE:BSX) by 4.6% in the 1st quarter, Holdings Channel reports. The fund owned 269,031 shares of the medical equipment provider’s stock after buying an additional 11,950 shares during the quarter. USS Investment Management Ltd’s holdings in Boston Scientific were worth $16,876,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of BSX. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the 2nd quarter worth approximately $26,000. Swiss RE Ltd. bought a new position in Boston Scientific during the 4th quarter valued at approximately $26,000. Garton & Associates Financial Advisors LLC bought a new position in Boston Scientific during the 4th quarter valued at approximately $26,000. Bangor Savings Bank raised its stake in Boston Scientific by 94.7% during the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 142 shares during the last quarter. Finally, Board of the Pension Protection Fund bought a new stake in Boston Scientific in the fourth quarter worth $29,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.7%

Boston Scientific stock opened at $42.98 on Thursday. Boston Scientific Corporation has a 12 month low of $42.25 and a 12 month high of $109.50. The stock has a fifty day simple moving average of $51.68 and a two-hundred day simple moving average of $69.93. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The firm has a market cap of $63.89 billion, a price-to-earnings ratio of 17.98, a PEG ratio of 0.82 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same period in the prior year, the company posted $0.75 earnings per share. The company’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts predict that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific announced that its board has approved a share repurchase program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its stock is undervalued.

Insiders Place Their Bets

In related news, Director Cheryl Pegus purchased 1,770 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the purchase, the director directly owned 1,770 shares of the company’s stock, valued at $99,987.30. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Edward J. Ludwig acquired 3,580 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were bought at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the acquisition, the director directly owned 25,359 shares of the company’s stock, valued at $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders acquired 9,800 shares of company stock valued at $554,012. 0.34% of the stock is owned by insiders.

Analysts Set New Price Targets

BSX has been the topic of a number of recent research reports. Oppenheimer set a $90.00 target price on Boston Scientific in a research note on Thursday, April 23rd. Truist Financial lowered their price target on Boston Scientific from $85.00 to $64.00 and set a “buy” rating for the company in a research report on Thursday, June 4th. Wells Fargo & Company reissued an “equal weight” rating and set a $55.00 price objective (down from $75.00) on shares of Boston Scientific in a research report on Thursday, May 28th. Wolfe Research lowered shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday, May 29th. Finally, Barclays decreased their target price on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a report on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $83.36.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific completed its POLARx Post Approval Study, adding fresh clinical data to its atrial fibrillation growth story and supporting the long-term outlook for its electrophysiology business. Boston Scientific’s POLARx Study Completion Adds Fresh Data to Atrial Fibrillation Growth Story
• Positive Sentiment: The company’s latest reported revenue growth remains strong, with Q1 sales up 11.6% year over year, which helps reinforce the durability of Boston Scientific’s core medtech franchise.
• Neutral Sentiment: Boston Scientific invested $1.5 billion for a 34% stake in MiRus and secured an option to buy its TAVR system, a strategic move that could expand its structural heart pipeline over time. Boston Scientific (BSX) Invests $1.5B in MiRus for Equity Stake and TAVR Acquisition Option
• Neutral Sentiment: Stifel lowered its price target to $65 from $75 but kept a Buy rating, while other analysts also trimmed earnings estimates only slightly; the cuts suggest some caution, but not a full deterioration in the long-term thesis. Stifel Cuts PT on Boston Scientific Corporation (BSX)- Here’s Why
• Negative Sentiment: Recent analyst commentary and social-media chatter focused on softer demand for the Watchman device, bundling pressure, and technical weakness near multi-year lows, which likely contributed to the stock’s decline. Boston Scientific Stock (BSX) Opinions on Recent Analyst Downgrades
• Negative Sentiment: Boston Scientific also declined in the latest session despite a broader market gain, reflecting investor concern that recent analyst revisions and product-specific pressures may outweigh the company’s fundamental growth. Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.